European Microbiome & Live Biotherapeutics 2026: Live-Biotherapeutic Products, Microbial CDMO, Industrial Microbiome

Aurealis Therapeutics (Kuopio, Finland) develops engineered live-biotherapeutic products using Lactococcus lactis as a delivery chassis for therapeutic proteins. The lead programme AUP1602-C (engineered L. lactis secreting CSF-1, SDF-1, and IL-4) targets diabetic foot ulcer treatment in clinical development — one of the directory-surfaced European clinical-stage LBP programmes. AlgiPharma (Sandvika, Norway) develops alginate-oligomer therapeutics including OligoG for cystic fibrosis biofilm disruption and antimicrobial resistance — adjacent to the live-biotherapeutic layer through its biofilm + microbial-modulation mechanism. The European Anti-Infectives layer is covered in the European Drug Discovery Services 2026 brief.

Human Biome Institute (Gdansk, Poland) is the directory-surfaced FMT (fecal microbiota transplantation) + donor-independent microbiome biotherapeutics operator. The institute builds manufacturing infrastructure for fecal-microbiota-derived therapeutics including donor screening, processing, characterisation, and clinical delivery — addressing the European regulatory frame for FMT (EMA + national competent authorities under classification debate between substance-of-human-origin and ATMP frameworks). For sponsors evaluating European FMT or donor-independent microbiome biotherapeutics partnership, Human Biome Institute is the directory-surfaced Polish operator.

Denmark concentrates the directory’s industrial microbial + enzyme + fermentation footprint through Novonesis (Hørsholm) — the merged group formed January 2024 from Novozymes (industrial enzymes) and Chr. Hansen (microbial cultures + food + health). Novonesis runs enzyme manufacturing, microbial culture production, and industrial fermentation across food + beverage + agriculture + biofuels + animal health + human health adjacencies, with adjacency to biopharma fermentation supply. While Novonesis is principally an industrial-biotech operator rather than a therapeutic LBP developer, its scale + culture-bank + fermentation infrastructure is the directory-surfaced European industrial-microbial backbone. TFTAK (Tallinn, Estonia) provides bioprocess optimisation + microbiome research + alternative-protein development infrastructure as a Baltic applied-microbiology research operator.

European microbial CDMO + bioprocessing concentrates at four directory operators. Lonza Visp (Switzerland) runs large-scale microbial fermentation as part of its integrated CDMO across mammalian + microbial + chemical + pDNA modalities. Wacker Biotech (Halle/Jena, Germany) runs industrial microbial biotechnology + process chemistry + biosolutions manufacturing using its ESETEC E. coli secretion expression platform. AGC Biologics (Heidelberg, Germany) provides CDMO services across mRNA + pDNA + microbial bioprocessing with GMP services. 3P Biovian (Turku, Finland) is the merged Finnish + Spanish CDMO providing biologics + viral vectors + plasmid DNA + aseptic fill-finish using microbial and mammalian platforms. The European CDMO Capacity 2026 and Viral Vector CDMO Europe 2026 briefs cover the wider CDMO + viral-vector layers.

European enzyme-tooling + microbial-engineering platforms include four directory operators. Genovis (Lund, Sweden) develops enzyme tools (IdeS / FabRICATOR, IgGZERO, GingisKHAN, others) for biologics sample preparation + analytical workflows — supporting downstream characterisation of antibody therapeutics. ArcticZymes (Tromsø, Norway) develops cold-adapted enzymes (heat-labile proteinases, polymerases, nucleases) sourced from Arctic marine microbes for molecular biology + diagnostic + bioprocessing applications. Caszyme (Vilnius, Lithuania) develops CRISPR-Cas technology including alternative Cas enzymes for genome editing + diagnostics. Biomatter (Vilnius) applies generative protein design + machine learning to enzyme engineering — covered in the European AI Drug Discovery 2026 brief. Myria Biosciences (Basel, Switzerland) works on synthetic biology + microbial drug discovery for undruggable targets.

European microbiome research connects to single-cell + microfluidics + sequencing infrastructure. Atrandi Biosciences (Vilnius) and Droplet Genomics (Vilnius) provide single-cell analysis + microfluidics + droplet technology for high-throughput microbial community characterisation. Solis BioDyne (Tartu) provides PCR reagents + molecular biology consumables. The European Genomics & Sequencing 2026 brief covers the genomics + microbial sequencing infrastructure. Industrial food + dairy fermentation operators are part of Novonesis’s portfolio (renamed Chr. Hansen + Novozymes group) — adjacent to but distinct from the therapeutic LBP layer covered here.

Match the decision to the modality. Engineered live-biotherapeutic clinical development (lactic-acid bacteria, diabetic foot ulcer, infectious disease): Aurealis Therapeutics (Kuopio). FMT + donor-independent microbiome biotherapeutics: Human Biome Institute (Gdansk). Industrial microbial + enzyme manufacturing + fermentation: Novonesis (Hørsholm). Bioprocess optimisation + microbiome research + alternative proteins (Baltic + applied): TFTAK (Tallinn). Large-scale microbial CDMO: Lonza Visp (Switzerland) or Wacker Biotech (Halle/Jena). Microbial bioprocessing + pDNA CDMO: AGC Biologics (Heidelberg) or 3P Biovian (Turku). Enzyme tools for biologics analytics: Genovis (Lund). Cold-adapted enzymes for molecular biology + diagnostics: ArcticZymes (Tromsø). CRISPR-Cas enzyme platform: Caszyme (Vilnius). Cystic fibrosis biofilm + antimicrobial alginate: AlgiPharma (Sandvika). The How to Pick a European Biotech Partner 2026 brief covers cross-modality partner selection.